Nanotechnology Law Report

Results of a pilot study on non-human primates and quantum dots

Several studies of possible toxic effects of quantum dots on humans have been done using cell cultures in petri dishes or rodents, usually white lab rats. But lab rats are related to humans only in that both are mammals.

In a recently published letter in Nature Nanotechnology,"A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots", published online 05/20/2012, Ling Ye and other authors based at PLA General Hospital in Beijing, SUNY-Buffalo, Nanyang Technological University, and Changchun University of Science and Technology, report the results of experiments where quantum dots where injected into male rhesus monkeys. Rhesus monkeys were chosen for this experiment since they are genetically and physiologically closer to humans than rodents and are less endangered than chimpanzees.

The authors report that the rhesus monkeys did not exhibit any ill effects from the injections:

A complete blood count (cbc) was performed at regular intervals and the results did not suggest any acute toxicity.

After 90 days, the study did find that quantum dots had accumulated in the liver, spleen, and kidneys and in lesser amounts in the heart, lungs, and other organs. Examinations of tissues from these organs found no abnormalities.

In conclusion, rhesus macaques intravenously injected with ~ 25 mg of a cadmium based quantum dot formulation survived without any evidence of toxicity. All measured biochemical markers were in the normal range. . . .However, given the persistence of elevated cadmium and selenium levels in organs after three months, longer term studies will be required to determine the ultimate fate of these heavy metals and any ill effects arising due to their presence. All data obtained in this pilot study suggest that the phospholipid micelle encapsulated quantum dot formulation has very low tosicity on the timescale considered. This suggests a potential role for quantum dots in human clinical applications, such as image guided surgery for tumour removal, where the advantages provided for quantum dots can outweigh the potential risk associated with accumulation of their constituent elements in the body.

 

Trackbacks (0) Links to blogs that reference this article Trackback URL
http://www.nanolawreport.com/admin/trackback/280370
Comments (0) Read through and enter the discussion with the form at the end
Porter Wright Morris & Arthur LLP
Washington, D.C. 1900 K Street,
NW, Suite 1110
Washington, DC 20006
Phone: 202-778-3000
Toll Free: 800-456-7962
Fax: 202-778-3063
Columbus Huntington Center
41 South High Street
Columbus, OH 43215-6194
Phone: 614-227-2000
Toll Free: 800-533-2794
Fax: 614-227-2100
Cleveland 925 Euclid Avenue
Suite 1700
Cleveland, OH 44115-1483
Phone: 216-443-9000
Toll Free: 800-824-1980
Fax: 216-443-9011
Cincinnati 250 East Fifth Street
Suite 2200
Cincinnati, OH 45202-5118
Phone: 513-381-4700
Toll Free: 800-582-5813
Fax: 513-421-0991
Dayton One Dayton Centre
Suite 1600
One South Main Street
Dayton, OH 45402-2028
Phone: 937-449-6810
Toll Free: 800-533-4434
Fax: 937-449-6820
Naples 9132 Strada Place
Third Floor
Naples, FL 34108-2683
Phone: 239-593-2900
Toll Free: 800-876-7962
Fax: 239-593-2990